Across TCGA pan-cancer cohorts, RNU7-165P RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RNU7-165P’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where RNU7-165P RNA is repressed in tumor relative to normal tissue. In most cancer types RNU7-165P is over-expressed in tumor, although a few such as PRAD show the opposite, repressed pattern.
PRAD and LUSC are the cancer types where RNU7-165P tumor–normal differential expression is most reproducible.